NCT05579314View on ClinicalTrials.gov

XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

November 16, 2024

Study Completion Date

November 16, 2024

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

XW014

Oral tablets

DRUG

Placebo

Matched oral placebo tablets

DRUG

XW014

Oral capsules

DRUG

Placebo

Matched oral placebo capsules

Trial Locations (3)

66219

ICON - Early Development Services, Lenexa

78209

ICON - Early Development Services, San Antonio

84124

ICON - Early Development Services, Salt Lake City

All Listed Sponsors
lead

Sciwind Biosciences USA Co., Ltd.

INDUSTRY